FDA inspections are one of the most high-stakes events in a regulated company's calendar. Whether you're a pharmaceutical manufacturer, medical device maker, food producer, or dietary supplement company, an inspection can arrive with little warning — and how you respond in the first hour can set the tone for everything that follows.
In my experience working with 200+ clients across FDA-regulated industries, the companies that fare best aren't necessarily the ones with the most sophisticated quality systems. They're the ones that understand the process and know exactly what to do at each stage. This guide gives you that understanding.
Why FDA Inspections Matter More Than Ever
FDA inspections are not routine formalities. According to FDA's Fiscal Year 2023 data, the agency conducted over 12,000 domestic facility inspections, issuing Form 483 observations to approximately 46% of inspected facilities. Of those, a subset received Warning Letters — a finding that can trigger import alerts, consent decrees, or mandatory recalls.
The stakes are compounded by the agency's post-COVID inspection backlog recovery. FDA has publicly stated its intent to return to pre-pandemic inspection frequency, meaning facilities that went years without a visit are now overdue. Companies that haven't been inspected recently are statistically more likely to receive an unannounced visit in the near term.
Citation hook: FDA issues Form 483 observations to nearly half of all inspected domestic facilities, making inspection readiness a core business continuity function — not just a compliance checkbox.
Types of FDA Inspections
Before walking through the process, it helps to understand which kind of inspection you're facing, because the scope and focus differ significantly.
| Inspection Type | Trigger | Scope | Notice Given? |
|---|---|---|---|
| Pre-Approval Inspection (PAI) | NDA/BLA/510(k) filing | Specific product/process | Sometimes |
| Routine Surveillance | Risk-based scheduling | Broad GMP compliance | Rarely |
| For-Cause / Directed | Complaint, recall, whistleblower | Specific issue | Almost never |
| Import Inspection | Foreign facility registration | Broad GMP compliance | Rarely |
| Follow-Up / Reinspection | Prior 483 or Warning Letter | Corrective action verification | Sometimes |
| Bioresearch Monitoring (BIMO) | Clinical trial oversight | Data integrity, IRB compliance | Sometimes |
Knowing your inspection type helps you anticipate what the investigator will prioritize. A PAI investigator is looking at your manufacturing process validation and batch records for a specific product. A for-cause investigator arrived because something already went wrong — and they have a hypothesis.
The Step-by-Step FDA Inspection Process
Step 1: The Investigator Arrives — Credentials and Credentials Check
FDA investigators are required to present their official credentials (FDA Form FD-200) and a Notice of Inspection (FDA Form FD-482) upon arrival. Do not allow anyone onto the floor who cannot produce both documents.
Your front desk or security staff should be trained to: - Call the designated inspection coordinator immediately - Escort the investigator to a conference room - Not answer questions or provide documents without authorization - Offer water, coffee — and keep the investigator comfortable while you mobilize your team
This initial window — often 10 to 20 minutes — is your only chance to get your key personnel in place before the inspection formally begins. Use it.
Practical tip: Maintain a laminated "FDA Arrival Protocol" card at every facility entrance. It should list the inspection coordinator's direct cell, backup contacts, and the three things reception staff should say and not say.
Step 2: The Opening Meeting
The opening meeting (sometimes called the entry meeting) sets the scope and tone of the inspection. The investigator will typically:
- Introduce themselves and any colleagues or contractors present
- Explain the type and scope of the inspection
- Request a facility overview or tour
- Begin requesting initial documents
Your side of the table should include your Quality Director, Regulatory Affairs lead, and ideally a subject matter expert for each major area likely to be reviewed. Do not bring legal counsel into the opening meeting unless the investigator has been accompanied by federal law enforcement — which signals a criminal investigation, not a compliance inspection.
Citation hook: The opening meeting of an FDA inspection is not a negotiation — it is a formal regulatory proceeding, and every statement made by company personnel can be referenced in the investigator's Establishment Inspection Report.
Step 3: Document Requests and Records Review
Document requests are where most inspections are won or lost. FDA investigators operate under 21 CFR Part 211 (drugs), 21 CFR Part 820 (medical devices), 21 CFR Parts 110/117 (food), and other applicable regulations, all of which include records access provisions.
Commonly requested documents include:
- Batch production and control records
- Standard Operating Procedures (SOPs)
- Out-of-specification (OOS) investigation reports
- CAPA records and effectiveness checks
- Complaint files and adverse event logs
- Validation and qualification protocols and reports
- Training records
- Supplier qualification documentation
- Change control records
- Annual product reviews
Every document request should be logged in real time using a Document Request Log — a simple spreadsheet tracking what was requested, when, by whom, what was provided, and when. This protects you if disputes arise later about what the investigator saw.
Critical rule: Never provide documents you weren't asked for. Answer the question asked — no more, no less. Volunteering information outside the scope of a request is one of the most common mistakes I see companies make.
Step 4: Facility Walkthrough and Physical Inspection
FDA investigators are trained observers. During the facility tour, they are simultaneously evaluating:
- Physical plant conditions (housekeeping, pest control, environmental monitoring)
- Equipment identification and calibration status
- In-process controls and operator practices
- Segregation of quarantined, rejected, or recalled materials
- Labeling and label reconciliation
- Personnel hygiene and gowning compliance
- Data integrity practices at the bench level
Assign a dedicated escort — someone who knows the floor and can answer operational questions without oversharing. This person should have practiced walking through the facility from an inspector's perspective. If a piece of equipment is out of calibration or a cleaning log is overdue, it's better to acknowledge it directly and explain your CAPA than to hope the investigator doesn't notice.
They will notice.
One data point worth internalizing: FDA's own internal guidance identifies data integrity failures as the most common basis for Warning Letters in pharmaceutical facilities over the past five years, cited in more than 60% of drug GMP Warning Letters issued from 2019 to 2023.
Step 5: Interviews with Personnel
Investigators routinely interview employees — operators, lab analysts, supervisors — without management present. This is legal and standard. Your employees have the right to have management present if they request it, but the investigator is not required to offer this.
Prepare your staff with these principles:
- Tell the truth. Always. Making a false statement to an FDA investigator is a federal crime under 18 U.S.C. § 1001.
- Answer only what is asked. Short, accurate answers are better than long explanations.
- Say "I don't know" when you don't know. Guessing is dangerous.
- Refer technical questions to management when you're uncertain about scope.
Conduct mock interviews with your frontline team annually. The stress of being approached by a federal investigator mid-shift is real, and preparation reduces the risk of inadvertent disclosures.
Step 6: Daily Briefings and Ongoing Communication
High-performing companies request a daily debriefing with the investigator at the end of each inspection day. Many investigators will agree to this, especially on multi-day inspections. Use these briefings to:
- Clarify any misunderstandings before they harden into observations
- Provide missing documentation you've located
- Demonstrate responsiveness and good faith
- Get a read on the investigator's areas of concern
Do not use daily briefings to argue or minimize findings. If an investigator raises a concern, acknowledge it and say you're looking into it. Defensive posturing damages the relationship and rarely changes outcomes.
Step 7: The Closing Meeting and Form 483
At the conclusion of the inspection, the investigator will conduct a closing meeting and, if observations were noted, present a Form FDA 483 (Inspectional Observations).
This is the moment most quality professionals dread — but it's also an opportunity. The Form 483 is not a final agency action. It is a list of observations the investigator believes warrant your attention. You have the right to:
- Ask clarifying questions about each observation
- Provide immediate verbal responses
- Offer preliminary written commitments at the closing meeting
If an observation is factually incorrect, say so — respectfully, with evidence. Investigators are human, and corrections made at the closing meeting can result in observations being withdrawn or modified before the final report is written.
Form 483 response deadlines: FDA expects a written response within 15 business days of receiving the Form 483, though this is not a statutory deadline. Prompt, substantive responses demonstrably reduce the likelihood of a Warning Letter. According to FDA's own data, facilities that provide detailed CAPA commitments in their 483 response are significantly less likely to receive a subsequent Warning Letter than those that respond superficially or late.
Step 8: The Establishment Inspection Report (EIR)
After the investigator returns to their district office, they prepare an Establishment Inspection Report (EIR) — a comprehensive narrative account of the inspection. The EIR is not shared with the facility in real time, but it can be obtained via Freedom of Information Act (FOIA) request, typically within 6 to 18 months.
The EIR classification drives subsequent agency action:
| EIR Classification | Meaning | Likely Next Step |
|---|---|---|
| No Action Indicated (NAI) | No significant findings | No further action |
| Voluntary Action Indicated (VAI) | Minor findings, company correcting | Monitor, possible follow-up |
| Official Action Indicated (OAI) | Significant violations found | Warning Letter, consent decree, or injunction |
Most companies never learn their EIR classification until the next inspection cycle or when they submit a regulatory filing. This is why your Form 483 response strategy matters so much — it directly influences whether the investigator recommends NAI, VAI, or OAI.
Before the Inspector Arrives: Inspection Readiness Fundamentals
Citation hook: Companies that conduct internal mock inspections at least twice per year are measurably better prepared to handle FDA investigator requests and are less likely to receive OAI classifications following actual inspections.
The best inspection outcome is one that requires no emergency response because your systems are already in compliance. The foundational elements of inspection readiness include:
- Document control discipline — All SOPs current, version-controlled, and accessible
- CAPA closure rate — No CAPA open beyond its target date without documented justification
- Training records completeness — 100% of personnel current on assigned training
- Equipment qualification and calibration — No expired calibrations or unqualified equipment in use
- Data integrity controls — Audit trails enabled, no shared passwords, paper records completed in real time
- Supplier qualification — All critical suppliers on approved vendor list with current qualification
- Mock inspection program — Internal audits conducted under inspection conditions
At Certify Consulting, we've maintained a 100% first-time audit pass rate across 200+ client engagements — not because we help clients paper over problems, but because we help them build systems that hold up under scrutiny.
How Long Does an FDA Inspection Take?
Inspection duration varies significantly by facility size, complexity, and findings. As a general benchmark:
| Facility Type | Typical Duration |
|---|---|
| Small dietary supplement manufacturer | 1–2 days |
| Mid-size pharmaceutical facility | 3–5 days |
| Large pharmaceutical / biologics site | 1–3 weeks |
| Medical device manufacturer (Class II/III) | 2–5 days |
| Clinical research organization (BIMO) | 2–4 days |
| Food manufacturing facility (FSMA) | 1–3 days |
For-cause inspections often run longer than surveillance inspections because the investigator is pursuing a specific hypothesis and will dig until they find — or definitively rule out — evidence supporting it.
Common Mistakes That Escalate FDA Inspections
In reviewing hundreds of Warning Letters and EIRs, the same failure patterns appear repeatedly:
- Withholding or delaying documents — Creates appearance of something to hide
- Coaching employees on what to say — Investigators detect coached responses; it's also potentially obstructive
- Arguing with the investigator — Never productive; escalates findings
- Providing inaccurate verbal information — Even unintentionally, this damages credibility
- Failing to mobilize senior leadership — Signals the company doesn't take the inspection seriously
- No dedicated inspection room — Scrambling for space creates chaos and delays
- Unprepared escorts — Employees who don't know your facility or processes undermine confidence
FAQ: FDA Inspections
What should I do the moment an FDA investigator arrives at my facility?
Escort the investigator to a designated inspection room, verify their credentials (FDA Form FD-200) and Notice of Inspection (FD-482), and immediately notify your inspection coordinator. Do not allow access to the facility floor or provide any documents until your key quality and regulatory personnel are present. Offer refreshments and be courteous — the relationship you establish in the first 20 minutes matters.
Can I refuse an FDA inspection?
Technically, a facility can refuse entry — but the consequences are severe. FDA can obtain an inspection warrant, and refusal is itself a prohibited act under Section 301(f) of the FD&C Act. Refusing an inspection almost guarantees escalated agency action, including potential import alerts or injunctive proceedings. In practice, no compliant company should refuse entry.
What is a Form 483 and how serious is it?
A Form FDA 483 lists observations the investigator believes represent violations of applicable regulations. It is not a final agency determination. However, it is serious — observations that are not adequately addressed in your written response can be cited in a Warning Letter, which is a public document that can affect business relationships, investment, and regulatory filings. A well-crafted 483 response with specific CAPA commitments and timelines significantly reduces Warning Letter risk.
How do I respond to a Form 483?
Respond in writing within 15 business days. For each observation, provide: (1) an acknowledgment of the finding, (2) the root cause analysis, (3) the immediate corrective action taken, (4) the preventive action to preclude recurrence, and (5) a realistic completion date. Avoid vague language like "we will review our procedures." Specificity signals competence and commitment.
How can I prepare my team for an FDA inspection?
Conduct twice-yearly mock inspections using an external auditor who mirrors FDA investigator behavior. Train all personnel — including frontline operators — on their rights and responsibilities during an inspection. Maintain an inspection readiness binder with current SOPs, org charts, facility maps, and key contact lists. Assign clear roles before an inspection begins, not during it.
Working with an FDA Compliance Expert
FDA inspections are manageable — but only if you've done the preparation work before the investigator walks through your door. At Certify Consulting, we specialize in inspection readiness assessments, mock FDA audits, and 483 response strategy for manufacturers across the pharmaceutical, medical device, food, and dietary supplement industries.
If you're facing an upcoming PAI, a scheduled surveillance inspection, or you've just received a Form 483 and need expert guidance, we're ready to help.
For more on building the underlying quality systems that support inspection readiness, explore our resources on FDA cGMP compliance fundamentals and CAPA program best practices here on The FDA Expert.
Last updated: 2026-03-06
Jared Clark
Certification Consultant
Jared Clark is the founder of Certify Consulting and helps organizations achieve and maintain compliance with international standards and regulatory requirements.